Human herpes simplex type-I virus UL-7 gene mutation attenuated strain as well as construction method and applications thereof

Abstract

The invention belongs to the fields of genetic engineering and genetic modification, and in particular relates to a human herpes simplex type-I virus UL-7 gene mutation attenuated strain as well as a construction method and applications of the human herpes simplex type-I virus UL-7 gene mutation attenuated strain. With the adoption of the technical scheme, the technical process and validation index for preparing the HSVI UL-7 mutation attenuated strain are perfected. After the UL-7 mutation attenuated strain is obtained, the corresponding detection confirmation is carried out on the attenuation features of the UL-7 mutation attenuated strain. Meanwhile, the corresponding study is made on the application possibility of the mutant strain virus as the HSVI attenuated live vaccine.

Description

technical field [0001] The invention belongs to the field of genetic engineering and genetic modification, and in particular relates to a human herpes simplex virus type I UL-7 gene mutation attenuated strain, a construction method and application. Background technique [0002] Human herpes simplex virus type I (Herpes Simplex Virus I, HSVI), as an important viral pathogen affecting human health, has been known to us for many years. The disease caused by it infecting the human body - herpes simplex, mainly occurs on the skin of the lips. It is also increasingly seen on the genital skin. The latter is mostly caused by herpes simplex virus type II (HSVII) infection. The seriousness of HSVI infection is that it not only causes severe painful herpes on the lips, but more importantly, the virus can enter the nerve cells with the trigeminal nerve as the main damaged tissue, and form a latent infection in it to form a pair of Lifelong effects on human body health. Therefore, th...

AI Technical Summary

Problems solved by technology

But so far, HSVI vaccine research has not seen significant progress. The main reasons are as follows: First, the HSVI gene structure is complex, so it is difficult to obtain attenuated vaccine strains with clear biological indicators by using traditional attenuation techniques. At the same time, its effectiveness and safety metrics are difficult to establish

Secondly, inactivated vaccines have never shown effective immunogenicity, and peptide vaccines prepared by genetic manipulation, such as subunit vaccines of HSVI capsid granule proteins gB, gD, gC, etc., have not been clinically tested in clinical trials. protective result

Images